Gene mutations, including Nucleophosmin (NPM1), FMS-like tyrosine kinase 3 (FLT3), and splicing factor mutations (e.g., SF3B1, SRSF2, U2 AF1), are recognized as key drivers of AML pathogenesis [83, 84]. This evidence concerns the gene NPM1 and acute myeloid leukemia.